Advertisement
Home 2018

Archives

Almost 63 percent of patients did not use opioids after having an elective procedure

Study Finds 31 Percent Use No Opioids After Surgery

0
At discharge, 92.2 percent of patients received an opioid prescription; nearly 63 percent unused
Eight factors contribute to postoperative pain after spine surgery

Eight Factors Predict Pain After Spine Surgery

0
Post-op pain strongly linked to number of classes of non-opioid analgesics used, remifentanil use
Non-invasive neuromodulation therapy using a custom stimulation pattern provides symptomatic relief from hand tremor in essential tremor

AAN: Neuromodulation Therapy Gives Relief From Hand Tremor

0
Non-invasive neuromodulation therapy using a custom stimulation pattern safe for essential tremor
Addition of an interspace between the popliteal artery and capsule of the posterior knee block and adductor canal block to periarticular injection is associated with less pain after total knee arthroplasty

Less Pain Post TKA With Addition of Peripheral Nerve Blocks

0
Lower numeric rating scale pain scores on ambulation on postoperative days zero, one, and two
For infants with type 1 spinal muscular atrophy who have two copies of the survival motor neuron (SMN) 2 gene

AAN: New Drug May Help Infants With Spinal Muscular Atrophy

0
RG7916 increases survival motor neuron protein level, with 6.5-fold increase noted with highest dose
For patients with episodic migraine who have failed prior preventive migraine treatments

AAN: Erenumab Shows Promise for Hard-to-Treat Migraine

0
Higher proportion of patients achieved a ≥50 percent reduction in mean monthly migraine days
Pembrolizumab is associated with significantly longer recurrence-free survival than placebo as adjuvant therapy for high-risk stage III melanoma

Adjuvant Pembrolizumab Beneficial in Stage III Melanoma

0
Pembrolizumab linked to significantly longer recurrence-free survival at 15-month follow-up
For metastatic non-small-cell lung cancer (NSCLC)

Adjuvant Pembrolizumab Beneficial in Metastatic NSCLC

0
And, nivolumab plus ipilimumab linked to better survival in NSCLC with high tumor mutational burden
Supplementation with n-3 fatty acids is not associated with significant benefit in dry eye disease

n-3 Fatty Acids Don’t Seem to Be of Any Benefit in Dry Eye Disease

0
Patients randomized to n-3 supplementation did not have significantly better outcomes versus placebo
About one in four low-income families with a member with atherosclerotic cardiovascular disease experience a high financial burden

High Financial Burden for Families of Patients With ASCVD

0
High burden of expenses for one in four low-income families; catastrophic burden for one in 10